Home | Promotion | BACK TO THE LAB | Checkpoint Killing Models

Checkpoint Killing Models

BACK TO THE LAB | Up to 25% OFF Selected Products for Immune Checkpoint Research

Evaluate immune checkpoint blockade and checkpoint-dependent tumor killing using ready-to-use tumor cell models and immune cell systems for immunotherapy research.

Explore Promotion Products →

Available now graphic for checkpoint killing models immunology research product

Checkpoint Killing Research

Evaluate immune checkpoint-dependent tumor killing using cell-based models supporting checkpoint inhibition, immune reactivation, cytotoxicity, and therapeutic response evaluation.

PD-1/PD-L1 Checkpoint Blockade

Evaluate PD-1/PD-L1 pathway inhibition and restoration of immune-mediated tumor killing using functional reporter and tumor cell models.

CTLA-4 Pathway Evaluation

Characterize CTLA-4-mediated immune suppression and functional recovery following checkpoint blockade.

Immune Checkpoint Cytotoxicity

Measure tumor cell killing following checkpoint inhibition using functional cytotoxicity and reporter-based assays.

Therapeutic Candidate Evaluation

Compare checkpoint inhibitor activity and downstream immune responses across different therapeutic candidates.

How Checkpoint Killing Is Evaluated

Checkpoint-dependent tumor killing involves immune suppression, checkpoint blockade, immune reactivation, and tumor cell elimination. AcceGen provides complementary cell models to support key stages of this workflow.

Pd1 pdl1 checkpoint mediated inhibition biological diagram of t cell and tumor cell

01 Checkpoint-Mediated Inhibition

PD-1 on T cells engages PD-L1 on tumor cells, suppressing T cell activation and downstream signaling.

Checkpoint blockade and t cell reactivation mechanism illustration with therapeutic antibody

02 Checkpoint Blockade & Reactivation

Anti-PD-1 or anti-PD-L1 antibodies disrupt receptor–ligand interactions, restoring immune signaling and T cell effector activity.

Quantitative readout diagram of reactivated t cell mediated tumor cell killing assay

03 Tumor Killing Quantification

Restored immune activity leads to tumor cell elimination, which can be quantitatively assessed using luciferase reporter models and other functional readouts.

Beyond PD-1/PD-L1, AcceGen provides models supporting CTLA-4, LAG-3, and TIGIT checkpoint research.

Research Models for Checkpoint Killing

Explore complementary cell models supporting immune checkpoint signaling, immune reactivation, tumor killing, and quantitative cytotoxicity assessment.

Tumor Cell & Reporter Models

Wild-type and luciferase-expressing tumor cells for checkpoint-dependent killing studies and quantitative assessment of tumor cell killing.

Checkpoint Signaling Reporter Models

Functional reporter cells for evaluating PD-1/PD-L1, CTLA-4, LAG-3, TIGIT, T cell activation, and related immune signaling pathways.

Immune Cell Models

PBMCs, purified T cells, and other immune cell models for functional checkpoint blockade and immune-mediated cytotoxicity studies.

Featured Products

UP TO 25% OFF Selected Cell Lines

Explore selected cell lines for T cell-mediated killing, CAR-T, and immunotherapy research.

CAT.#	Product / Cell Line	Cell Origin	Key Features	Recommended Applications	Lead Time
ABC-TC621S	MC38	Murine colorectal carcinoma	PD-L1-positive	PD-1/PD-L1 blockade evaluation	1–3 weeks
ABC-TC0197	CT-26	Murine colorectal carcinoma	PD-L1-positive	PD-1/PD-L1 blockade evaluation	1–3 weeks
ABC-TC0062	B16-F10	Murine melanoma	Low basal PD-L1 expression; inducible upon stimulation	Immune checkpoint research model	1–3 weeks
ABC-TC0026	A375	Human melanoma	PD-L1-positive	PD-1/PD-L1 blockade assays	3–5 weeks
ABC-TC0032	A549	Human non-small cell lung carcinoma	PD-L1-positive	PD-1/PD-L1 blockade assays	1–3 weeks
ABC-TC0337	HCT116	Human colorectal carcinoma	PD-L1-positive	Immune checkpoint research model	1–3 weeks
ABC-TC0924	Raji	Human Burkitt lymphoma	PD-L1-positive; inducible upon stimulation	Immune checkpoint co-culture assays	1–3 weeks
ABC-TC1258	U-87 MG	Human glioblastoma	PD-L1-positive	Neuro-oncology immune checkpoint studies	1–3 weeks
ABC-TC0651	MDA-MB-231	Human triple-negative breast cancer	PD-L1-positive	Breast cancer immune checkpoint studies	1–3 weeks
ABC-TC0591	LLC	Murine lung carcinoma	PD-L1-positive	Murine lung cancer model studies	1–3 weeks
ABC-RC193H	MC38-Luc	Murine colorectal carcinoma	Constitutive luciferase reporter cell line	PD-1/PD-L1 blockade evaluation	In stock
ABC-RC587H	CT-26-Luc	Murine colorectal carcinoma	Constitutive luciferase reporter cell line	PD-1/PD-L1 blockade evaluation	2–3 weeks
ABC-RC289H	B16-F10-Luc	Murine melanoma	Constitutive luciferase reporter cell line	Immune checkpoint research model	2–3 weeks
ABC-RC017H	A375-Luc	Human melanoma	Constitutive luciferase reporter cell line	PD-1/PD-L1 blockade assays	2–3 weeks
ABC-RC130D	A549-Luc	Human non-small cell lung carcinoma	Constitutive luciferase reporter cell line	PD-1/PD-L1 blockade assays	2–3 weeks
ABC-RC173H	HCT116-Luc	Human colorectal carcinoma	Constitutive luciferase reporter cell line	Immune checkpoint research model	1–3 weeks
ABC-RC206H	Raji-Luc	Human Burkitt lymphoma	Constitutive luciferase reporter cell line	Immune checkpoint co-culture assays	1–3 weeks
ABC-RC223H	U-87 MG-Luc	Human glioblastoma	Constitutive luciferase reporter cell line	Neuro-oncology immune checkpoint studies	2–3 weeks
ABC-RC037Z	MDA-MB-231-Luc	Human triple-negative breast cancer	Constitutive luciferase reporter cell line	Breast cancer immune checkpoint studies	In stock
ABC-RC190H	LLC-Luc	Murine lung carcinoma	Constitutive luciferase reporter cell line	Murine lung cancer model studies	2–3 weeks
ABC-TC3726	Human PBMC	Healthy donors	Contains T cells and other immune cell populations	Immune checkpoint blockade assays	4 weeks
ABC-TC3994	Human CD3+ T Cells	Isolated from PBMCs	Purified T cells	PD-1 expression studies and functional validation assays	4 weeks
ABC-TC3993	Human CD4+ T Cells	Isolated from PBMCs	T helper cells	Immune checkpoint functional validation assays	4 weeks
ABC-TC4005	Human CD8+ T Cells	Isolated from PBMCs	Cytotoxic T lymphocytes	Cytotoxicity assays and immune checkpoint blockade studies	4 weeks
ABC-TC4002	Human Treg Cells	Isolated from PBMCs	CD4+CD25+FoxP3+ regulatory T cells	Immunosuppression studies	4 weeks
ABC-H0081X	Human Primary Macrophages	Differentiated from monocytes	M1/M2 polarization-compatible	Immunosuppressive tumor microenvironment models	6 weeks
ABC-HP029X	Mouse PBMC	C57BL/6 mouse strain	Contains mouse T cells and other immune cells	Mouse immune checkpoint model studies	4 weeks
ABC-TC088G	Mouse CD3+ T Cells	Isolated from mouse PBMCs	Mouse T cells	Mouse immune checkpoint blockade assays	4 weeks
ABC-RC179F	Human PD-1 (Luc) Reporter Cell Line	Reporter cell background	PD-1 pathway luciferase reporter	PD-1/PD-L1 immune checkpoint signaling assays	2–4 weeks
ABC-RC098F	Human CTLA-4 Reporter Jurkat Cell Line	Jurkat T-cell background	CTLA-4 checkpoint reporter	CTLA-4 pathway and checkpoint blockade assays	2–4 weeks
ABC-RC186Y	LAG3 Reporter Jurkat Cell Line	Jurkat T-cell background	LAG-3 checkpoint reporter	LAG-3 pathway and checkpoint blockade assays	2–4 weeks
ABC-RC107F	TIGIT/CD226 Reporter Jurkat Cell Line	Jurkat T-cell background	TIGIT/CD226 checkpoint reporter	TIGIT pathway and checkpoint blockade assays	2–4 weeks
ABC-X0518F	CTLA-4 CHO-K1 Cell Line	CHO-K1 background	CTLA-4 overexpression model	Ligand binding and immune checkpoint assay development	2–4 weeks
ABC-X0540F	PDCD1 (PD-1) CHO-K1 Cell Line	CHO-K1 background	PD-1 overexpression model	Ligand binding and PD-1 pathway assay development	2–4 weeks
ABC-X0142Y	Human LAG3 CHO-K1 Cell Line	CHO-K1 background	LAG-3 overexpression model	Ligand binding and LAG-3 pathway assay development	2–4 weeks
ABC-X0561F	TIGIT CHO-K1 Cell Line	CHO-K1 background	TIGIT overexpression model	Ligand binding and TIGIT pathway assay development	2–4 weeks

Checkpoint Killing Models

BACK TO THE LAB | Up to 25% OFF Selected Products for Immune Checkpoint Research

Checkpoint Killing Research

PD-1/PD-L1 Checkpoint Blockade

CTLA-4 Pathway Evaluation

Immune Checkpoint Cytotoxicity

Therapeutic Candidate Evaluation

How Checkpoint Killing Is Evaluated

01 Checkpoint-Mediated Inhibition

02 Checkpoint Blockade & Reactivation

03 Tumor Killing Quantification

Research Models for Checkpoint Killing

Tumor Cell & Reporter Models

Checkpoint Signaling Reporter Models

Immune Cell Models

Featured Products

UP TO 25% OFF Selected Cell Lines

Let's Advance Life Science Research Together